PubMed Health⌕ Search

Biomedical subjects

K Antoniewicz

Publications and source records attributed to K Antoniewicz.

11 recordsLinked to original sources
PubMed1996

[Peritoneal blood flow and peritoneal transfer parameters during intermittent peritoneal dialyses performed with administration of sodium nitroprusside or chlorpromazine].

Effective peritoneal capillary blood flow (EPBF) was evaluated by calculation of diffusive mass transport coefficient of CO2 during intermittent peritoneal dialysis performed with intraperitoneal administration of sodium nitroprusside (NP, 5 mg/l of dialysis solution) or chlorpromazine (Cl-Prom, 2.5 mg/l of dialysis solution). Peritoneal transfer rates of substances of different molecular size and charge were simultaneously examined and compared with EPBF. During NP or Cl-Prom administration, EPBF was respectively 220 +/- 40 (n = 11) and 224 +/- 29 (n = 10) ml/min. These values were insignificantly higher than those obtained during dialyses without drugs (169 +/- 16 ml/min, n = 10). NP and Cl-Prom did not cause any significant changes in peritoneal transfer of CO2. Transfer rates of HCO3 and tCO2 were increased only with NP. Both drugs enhanced peritoneal removal of Na+, K+, urea, uric acid and total protein, but with similar EPBF during the use of both drugs, the effect of NP was more pronounced. The obtained results indicate that EPBF is not a major factor responsible for enhanced peritoneal transfer rates during dialyses performed with NP or Cl-Prom.

Carbon Dioxide↗
PubMed1996

[Uremic polyneuropathy in patients treated conservatively (nondialyzed) or treated with dialysis].

Uremic polyneuropathy is a common complication in dialyzed patients (pts). In 37 end stage renal disease (ESRD) pts the electroneurophysiological (ENF) parameters and serum creatinine (Pcr), guanidino compounds (GC) and guanidinosuccinic acid (GSA) levels were studied. There were 21 nondialyzed (ND), 10-hemodialyzed (HD) and 6-intermittently peritoneally dialyzed (IPD) pts. The following ENF parameters on both upper extremities, using method described by Buchtal and Rosenfalck, were performed: sensory nerves (nn.) conduction velocity, amplitude of evoked potential, subjective and objective impulse and motor nerve-conduction velocity. Cr level in serum was measured by enzymatic method, GC-by Rosenberg, Ennor, Morison method, modified by Szczepkowska. GSA isolation was performed by column chromatography. The results indicated disturbances in peripheral nn. function in all studied groups of pts and did not correlate with levels of uremic toxins in serum. However, it does not mean, that sum of the accumulated various toxic metabolites in ESRD pts, does not influence the development of polyneuropathy. The degree of impairment of peripheral nn. conduction in ESRD did not differ significantly between ND and HD or IPD pts. We did not notice, any significant differences in the degree of polyneuropathy in HD or IPD pts.

Adult↗
PubMed1996

[Effect of furosemide on transperitoneal transport of guanidine derivatives: in vitro studies].

The transperitoneal transport dynamics (removal) of guanidinoacetic acid (GAA) and guanidinosuccinic acid (GSA) has been determined in vitro in the control conditions and after application of furosemide (10(-4) mmol/l) on the mesothelial side of the membrane. GAA peritoneal transfer values, as a rule, were higher than GSA and equaled at mean, in the control series of experiments 0.132 i 0.068 mg x 10(-4) x cm-2 x s-2, respectively. Furosemide decreased GSA passage in 30 min after it addition by about 30%, but GSA transfer diminished later, in 120 min., by about 37%. Therefore, mean GAA transport values before (30-90 min.) and after application of furosemide (120-210 min.) were not statistically significant differentiated, whereas GSA transport parameters were lowered by about 40%. Heterogeneity of the peritoneal GAA and GSA transport dynamics in the control series of the experiments, as well as in the series with furosemide, may be related to the physico-chemical differences (e.g. molecular mass) of the analysed derivates.

Animals↗
PubMed1995

Peritoneal blood flow and peritoneal transfer parameters during dialysis with administration of drugs.

Effective peritoneal capillary blood flow (EPBF) was evaluated by calculating the diffusive mass transport coefficient of carbon dioxide during intermittent peritoneal dialysis (IPD) performed with the intraperitoneal administration of sodium nitroprusside (NP), chlorpromazine (CP), or isoproterenol (IP) in the doses 5, 2.5, and 0.5 mg/L, respectively. Peritoneal transfer rates of substances of different molecular size and charge were simultaneously examined and compared with EPBF. EPBF (mL/min) was 220 +/- 40 (+/- SEM) for NP (n = 11), 224 +/- 29 for CP (n = 10), and 243 +/- 35 for IP (n = 10). These values did not differ significantly from those obtained during dialysis without drugs (223 +/- 22 mL/min, n = 20). NP, CP, and IP did not cause any significant changes in peritoneal transfer of carbon dioxide. Transfer rates of bicarbonate and total carbon dioxide were increased only with NP. All drugs enhanced the peritoneal removal of sodium, potassium, urea, and uric acid. Total protein loss was enhanced by all drugs except IP. With statistically similar EPBF during dialysis, the augmenting effect of NP and IP on small solute removal was the most pronounced. These results indicate that EPBF is not a major factor in the changes in peritoneal transfer rates during dialysis performed with NP, CP, or IP.

Bicarbonates↗
PubMed1994

Effective peritoneal blood flow (EPBF) and patient characteristics.

The aim of these studies was a comparison of effective peritoneal blood flow (EPBF) during intermittent peritoneal dialysis (IPD) in uremic patients with varying primary renal disease, sex, age, body weight, and IPD duration. EPBF was estimated by calculation of diffusive mass transfer coefficient (KBD) of carbon dioxide at 2.5 min dwell of 1.5% glucose dialysis solution (2 L). EPBF estimated during IPD in 21 patients was a mean of flow rates obtained in each patient at the beginning, in the middle, and at the end of 1-2 dialyses. Our results suggest that EPBF during IPD is not significantly dependent on primary renal disease, sex, age, and body weight, nor does it change during the first few months of IPD.

Adolescent↗
PubMed1993

Effective peritoneal capillary blood flow and peritoneal transfer parameters.

In uremic patients peritoneal transfer was evaluated at 0-45-minute dwells in exchanges 3-5,9-11, and 15 -17 of single intermittent peritoneal dialysis (IPD) and compared to effective peritoneal blood flow (EPBF) simultaneously estimated as KBD for CO2 gas using the two-sample model of Garred et al. for a 2.5-minute dwell. During single IPD, a decrease in peritoneal transfer of HCO3-,tCO2,K+, and urea was observed (lower values of transfer in exchanges 15-17 than in exchanges 3-5). With a dialysis solution with pH 7.25, there were higher values of peritoneal clearances (Cp) for CO2 gas during the entire 45-minute dwell compared to respective values obtained with a pH 6.22 solution. Transfer parameters of urea and uric acid were also higher with a dialysis solution with pH 7.25, but there were significant differences only during the first 5-20 minutes of the dwell. All mentioned differences were not dependent on EPBF. Significant correlations between EPBF and peritoneal transfer parameters were shown only for CO2 gas, HCO3-, and tCO2. We consider these findings to be the correlation between the transfer of CO2 gas (not EPBF) and the transfer of other forms of CO2. Our data provide evidence that peritoneal transfer is not limited by changes in EPBF occurring during IPD in clinically stable uremic patients.

Bicarbonates↗
PubMed1993

An indirect estimation of effective peritoneal capillary blood flow in peritoneally dialyzed uremic patients.

The aim of this study was to evaluate the effective peritoneal capillary blood flow (EPBF) during intermittent peritoneal dialysis in uremic patients through the calculation of the diffusive mass transfer coefficient (KBD) of carbon dioxide gas. Examinations were performed during dialysis with the use of dialysis solution No. 1 (Polfa, Poland) with pH 6.30 (n = 10) or pH 7.25 (n = 10). The KBD of carbon dioxide was calculated at 2.5 minutes' dwell time. EPBF was estimated at the beginning (exchanges 3-5), in the middle (exchanges 9-11), and at the end (exchanges 15-17) of dialysis. KBD values of carbon dioxide, obtained during the above exchanges, yield EPBF of, respectively, 2.56 +/- 0.31, 2.63 +/- 0.25, and 2.59 +/- 0.44 mL/min/kg body weight for the pH 6.30 solution, and 1.84 +/- 0.25, 2.38 +/- 0.27, and 2.21 +/- 0.29 mL/min/kg body weight for the pH 7.25 solution. Our results yield EPBF greater than previously estimated and confirm suggestions that EPBF in humans exceeds 100 mL/min.

Animals↗
PubMed1990

[Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis].

The paper was performed in order to evaluate the influence of sulfinpyrazone given orally in the doses of 400 mg to 16 uraemic patients during intermittent peritoneal dialysis on transperitoneal and renal transfer of different molecular weight substances. It was shown that sulfinpyrazone causes the increase in dialysate excretion of uric acid, sodium and protein but does not influence the transperitoneal transfer of water, potassium, creatinine, glucose, heparin and acetic acid. Renal function determined by diuresis volume as well as clearance of sodium, potassium, creatinine, uric acid and protein remained unchanged after the drug administration. Thus, when sulfinpyrazone is used during peritoneal dialysis a possibility of its action on the peritoneal membrane permeability should be taken into consideration.

Adult↗
PubMedDate not supplied

[Effect of intraperitoneal furosemide administration on levels of +proteins+ in plasma and signs of their ability to be dialyzed during intermittent peritoneal dialysis].

The study aimed at evaluating an effect of intraperitoneal furosemide on plasma proteins such as albumins, globulins, IgG and IgA and their loss during dialysis. An experiment involved 18 patients with critical renal failure treated with intermittent peritoneal dialyses. Furosemide was administered intraperitoneally with dialysing fluid (40 mg/1) in a total dose of 240 mg. Each patient underwent 2 dialyses of 14 exchanges each. The first dialysis without furosemide served as a control of plasma protein loss during conventional dialysis with a fluid of 369 mOsm/kg at flow rate 2.4 l/hour. Furosemide was given during the second dialysis during three consecutive exchanges. An effect of furosemide on plasma proteins was compared with the results obtained before and after its administration. It was found that furosemide did not change plasma proteins levels and does not increase their loss during exchanges of dialysing fluid containing this drug; during dialysing fluid exchanges without furosemide some indices of IgG and IgA dialysis are significantly decreased due to an increase in ultrafiltration following furosemide cessation. It is important for the increase in intermittent peritoneal dialyses efficiency with the aid of furosemide that its short-term administration does not increase proteins loss during dialysis, if their molecular weight is not exceeding 69,000.

Adult↗
PubMedDate not supplied

[Levels of plasma proteins in patients with ene stage renal failure treated with peritoneal dialysis with an addition of furosemide to dialysis fluid].

This study aimed at evaluating an effect of repeated intraperitoneal furosemide administration on plasma proteins in patients with uremia given the drug to increase intermittent peritoneal dialysis efficiency. Patients (n = 6) dialysed for 48-60 hours per week furosemide was added to dialysis fluid in the dose of 1.2-2.0 g per 1 dialysis weekly for 3 months. A control group consisted of patients (n = 6) dialysed without furosemide. Plasma total proteins, albumin, total globulins, IgG, and IgA were determined in all patients. At the same time, plasma furosemide levels were monitored. A 3-month treatment with dialyses supplemented with furosemide decreased plasma protein levels especially IgG (p < 0.5) in comparison with dialyses without the drug. Furosemide plasma levels remained below ototoxic levels (over 50 micrograms/mL) during the treatment.

Adult↗